» Articles » PMID: 36933595

CRISPR-Cas for Genome Editing: Classification, Mechanism, Designing and Applications

Overview
Publisher Elsevier
Date 2023 Mar 18
PMID 36933595
Authors
Affiliations
Soon will be listed here.
Abstract

Clustered regularly interspersed short pallindromic repeats (CRISPR) and CRISPR associated proteins (Cas) system (CRISPR-Cas) came into light as prokaryotic defence mechanism for adaptive immune response. CRISPR-Cas works by integrating short sequences of the target genome (spacers) into the CRISPR locus. The locus containing spacers interspersed repeats is further expressed into small guide CRISPR RNA (crRNA) which is then deployed by the Cas proteins to evade the target genome. Based on the Cas proteins CRISPR-Cas is classified according to polythetic system of classification. The characteristic of the CRISPR-Cas9 system to target DNA sequences using programmable RNAs has opened new arenas due to which today CRISPR-Cas has evolved as cutting end technique in the field of genome editing. Here, we discuss about the evolution of CRISPR, its classification and various Cas systems including the designing and molecular mechanism of CRISPR-Cas. Applications of CRISPR-Cas as a genome editing tools are also highlighted in the areas such as agriculture, and anticancer therapy. Briefly discuss the role of CRISPR and its Cas systems in the diagnosis of COVID-19 and its possible preventive measures. The challenges in existing CRISP-Cas technologies and their potential solutions are also discussed briefly.

Citing Articles

Precision therapeutic targets for HPV-positive cancers: an overview and new insights.

Huang Y, Wang J, Yang W, Hou F, Feng X Infect Agent Cancer. 2025; 20(1):17.

PMID: 40069817 PMC: 11900425. DOI: 10.1186/s13027-025-00641-7.


Important applications of DNA nanotechnology combined with CRISPR/Cas systems in biotechnology.

Huang Y, Chen Z, Huang H, Ding S, Zhang M RSC Adv. 2025; 15(8):6208-6230.

PMID: 40008014 PMC: 11851101. DOI: 10.1039/d4ra08325c.


Characterization of Five CRISPR Systems in FACHB-524 with Focus on the In Vitro Antiviral Activity of One CRISPR System.

Zeng M, Zhang Q, Ke F Int J Mol Sci. 2025; 26(4).

PMID: 40004028 PMC: 11855584. DOI: 10.3390/ijms26041554.


New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14.

Ali Agha A, Al-Samydai A, Aburjai T Heliyon. 2025; 11(2):e42013.

PMID: 39906792 PMC: 11791237. DOI: 10.1016/j.heliyon.2025.e42013.


Developing a Versatile Arsenal: Novel Antimicrobials as Offensive Tools Against Pathogenic Bacteria.

Ma J, Lu Z Microorganisms. 2025; 13(1).

PMID: 39858940 PMC: 11767912. DOI: 10.3390/microorganisms13010172.